Surgery for solid-dominant lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of segmentectomy, a surgical procedure, for patients with solid-dominant invasive lung adenocarcinoma measuring 2-3 cm. The study will assess the 5-year disease-free survival rates and post-operative lung function of participants. Eligible patients will undergo segmentectomy and will be monitored for their recovery and outcomes over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who sign the informed consent form and are willing to complete the study according to the plan;
* Aged from 18 to 80 years old;
* ECOG equals 0 or 1;
* Not receiving lung cancer surgery before;
* Confirmed to be invasive lung adenocarcinoma intraoperatively or postoperatively;
* Ground glass-dominant lung nodules
* Consolidation-to-tumor ratio (CTR) ranges from 0.5 to 1, and tumor size ranges from 2 to 3cm;
* cN0 without distant metastasis;
* Tumors could be completely resected assed by surgeons;
* Not receiving chemotherapy or radiotherapy before.

Exclusion Criteria:

* CTR is not 0.5-1, or size is not 2-3cm;
* Tumors could not be completely resected assed by surgeons;
* Not lung adenocarcinoma diagnosed cytologically or pathologically;
* Receiving lung cancer surgery before;
* Receiving radiotherapy or chemotherapy.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Haiquan Chen, M.D. — Fudan University
• Study coordinator: Fangqiu Fu, M.D.
• Email: fufangqiu12@163.com
• Phone: +86-13122677592

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Surgery for early-stage lung cancer with ground glass nodules

  This study is testing if a lung-sparing surgery called segmentectomy can help people with early-stage lung cancer live longer and breathe better after treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05717803

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Force feedback in robotic lung resection: does gentler instrument touch help recovery?

  This study tests whether using Force Feedback instruments during robotic lobectomy or segmentectomy leads to faster recovery and fewer complications for adults undergoing these procedures.

  Recruiting Ohio State University · Columbus, Ohio · NCT07660900

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Pre-incisional ropivacaine plus diprospan to relieve pain after VATS

  This study tests whether injecting ropivacaine with diprospan before surgery can reduce postoperative pain for adults and children undergoing VATS lung surgery.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07626489

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.